SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more
RECALIBRATE YOUR HEALTHCARE STRATEGY
Learn 4 strategic pivots for 2025 and beyond.
Learn more

Library

| Daily Briefing

The mu variant: What you need to know


As the delta variant continues to spread in the United States, a new variant, called mu, has been deemed a "variant of interest" by the World Health Organization (WHO)—and preliminary data suggests that prior infection and vaccination may not provide strong immunity. 

How much worse will the 'delta surge' get? Watch these 7 factors.

What is the mu variant?

According to WHO, the mu variant, or B.1.621, was first detected in January 2021 in Colombia.

Since its identification, the mu variant has been detected in 42 different countries. While transmission of the mu variant is declining globally—accounting for less than 0.1% of current infections worldwide—it accounts for a significant portion of Covid-19 cases in Colombia (39%) and Ecuador (13%).

The mu variant has also been spotted in 49 states in the United States—and recently infected 167 people in Los Angeles County—but it has not yet been labeled a variant of interest by CDC. According to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical advisor to the White House, the United States is monitoring the new variant, but it remains relatively uncommon in the nation, where delta currently accounts for 99% of all Covid-19 cases.

In its weekly epidemiological report, WHO stated that data presented to WHO's Virus Evolution Working Group show the mu "variant has a constellation of mutations that indicate potential properties of immune escape," including preliminary data showing "a reduction in neutralization capacity of convalescent and vaccine sera similar to that seen for the [b]eta variant."

While further studies are needed to confirm the initial data, WHO categorized the mu variant as a "variant of interest" due to its potential impact on the body's immune response and its significant community transmission.  Fauci reiterated the point, noting that while mu "has a constellation of mutations that suggests it would evade certain antibodies," there's a need for further clinical data.

New variants are to be expected

According to Advisory Board's Rachel Woods, it's important to acknowledge that new coronavirus variants are to be expected—but the fact that a variant is "new" doesn't mean that it's "worse," or even different from prior variants in any clinically significant way.

Woods suggests asking additional questions as evidence emerges on new variants, including: How transmissible is the new variant? Does it commonly lead to severe infection, hospitalization, and/or death? And perhaps most importantly, do current vaccines protect against serious illness caused by this variant?

Fauci added, "Bottom line, we are paying attention to it. We take everything like that seriously, but we don't consider it an immediate threat right now." (McCarthy, New York Times, 9/2; Saric, Axios, 9/1; Choi, The Hill, 9/1; Lin, Los Angeles Times, 9/6; Rivas, Fox News, 9/7)


How much worse will the 'delta surge' get? Watch these 7 factors.

looking aheadJust how worried should you be about the delta variant? Advisory Board's Yulan Egan takes a deep dive into this question, detailing seven factors you should watch closely (and two to ignore) to determine just how deadly and disruptive the variant will prove to be.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

MORE FROM TODAY'S DAILY BRIEFING

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.